Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Licenses Neural Stem Cell Line from Buck Institute

NEW YORK (GenomeWeb News) - Invitrogen said today that it has licensed an engineered neural stem cell line from the Buck Institute for Age Research.
 
Invitrogen said that the stem cell line, BG01 Olig2-GFP, has been engineered to track the Olig2 gene, which controls a protein that maintains a neural stem cell's ability to replicate early in brain development, and then directs it to form a particular type of neural cell.
 
Joydeep Goswami, vice president of primary and stem cell systems at Invitrogen, said that the company plans to offer the cell line to its customers as well as to “further develop products from the line that will serve as valuable tools in neural stem cell research.”
 
Financial terms of the agreement were not provided.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.